46 results on '"D'Ippolito, Elvira"'
Search Results
2. Multiplexed imaging and automated signal quantification in formalin-fixed paraffin-embedded tissues by ChipCytometry
3. Advances in preclinical TCR characterization: leveraging cell avidity to identify functional TCRs
4. Role of miRNAs in the tumour-mediated vascularisation of triple negative breast cancer
5. Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through ‘reverse phenotyping’
6. T cell engineering for adoptive T cell therapy: safety and receptor avidity
7. Multimodal immune cell phenotyping in GI biopsies reveals microbiome-related T cell modulations in human GvHD
8. A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells.
9. Supplementary Figure S1 from miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
10. Supplementary Tables 1 through 4 from miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
11. Supplementary Figure legends from miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
12. Data from miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
13. Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression
14. RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers
15. PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells
16. Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer
17. The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer
18. SARS-CoV-2 CD8+ T cell killing assays using replicating viruses and transgenic antigens
19. Gene Signatures of T-Cell Activation Can Serve as Predictors of Functionality for SARS-CoV-2-Specific T-Cell Receptors
20. Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity
21. ChipCytometry for multiplexed detection of protein and mRNA markers on human FFPE tissue samples
22. CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients
23. Global koff‐rates of polyclonal T‐cell populations merge subclonal avidities and predict functionality
24. Global koff2̆010rates of polyclonal T\0̆10cell populations merge subclonal avidities and predict functionality
25. Phantosmia, Parosmia, and Dysgeusia Are Prolonged and Late-Onset Symptoms of COVID-19
26. Recruitment of highly functional SARS-CoV-2-specific CD8+T cell receptors mediating cytotoxicity of virus-infected target cells in non-severe COVID-19
27. Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through 'reverse phenotyping'
28. COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
29. Single-cell RNA sequencing revealsin vivosignatures of SARS-CoV-2-reactive T cells through ‘reverse phenotyping’
30. Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells
31. Abstract PR05: T-cell receptor (TCR)-based immunotherapy in pediatric malignancy: Addressing the challenge of early metastasis and low immunogenicity
32. Global koff‐rates of polyclonal T‐cell populations merge subclonal avidities and predict functionality.
33. Additional file 2: of The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer
34. MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab
35. Abstract 5437: miR-302b as adjuvant therapeutic tool to improve chemotherapy efficacy in human triple-negative breast cancer
36. T cell engineering for adoptive T cell therapy: safety and receptor avidity.
37. miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
38. Abstract 1068: The promise of miR-205 in HER2+ breast cancer: predicting response to Trastuzumab and overcoming resistance
39. Abstract A47: A microRNA signature identifies subtypes of triple-negative breast cancer and reveals miR-342-3p as regulator of a lactate metabolic pathway through silencing monocarboxylate transporter 1
40. Abstract A18: miR-9 and miR-200 regulate PDGFRβ-mediated endothelial differentiation of neoplastic cells in triple-negative breast cancer
41. Abstract 4381: MiR-205 and Trastuzumab: Potential as adjuvant therapeutic tool and predictive biomarker
42. MicroRNAs and Triple Negative Breast Cancer
43. SARS-CoV-2 CD8+T cell killing assays using replicating viruses and transgenic antigens
44. Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells.
45. Recruitment of highly cytotoxic CD8+T cell receptors in mild SARS-CoV-2 infection
46. Global k off -rates of polyclonal T-cell populations merge subclonal avidities and predict functionality.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.